Post Offer Free
Wuhan Yuancheng Gongchuang Technology Co,ltd
Wuhan Yuancheng Gongchuang Technology Co,ltd

China Anti-Cancer API 99% Raloxifene HCl CAS 84449-90-1 For Cancer Treatment manufacturer

2nd

Gold Index: 167631

You are here: home  > Pharmaceutical raw material  > Other pharmaceuticals  > Anti-Cancer API 99% Raloxifene HCl CAS 84449-90-1 For Cancer Treatment

Anti-Cancer API 99% Raloxifene HCl CAS 84449-90-1 For Cancer Treatment 

Price: 90.0 USD 
Payment Terms: T/T,WU,Money Gram 
Place of Origin: Hubei, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: disguise package or as requ...
Brand Name: gongchuang
Purity: 99%
source: Gefitinib source
supplier: Gefitinib supplier
Usage: Gefitinib Usage
purity: 99% min
Standard: USP/BP/USP
Production Capacity: 500kg//month
Delivery Date: 4-15days
CAS No.: 82640-04-8
Alias: Gefitinib
usage: Gefitinib usage
price: Gefitinib price
effects: medcine raw
Appearance: powder

Anti Estrogen Powder Raloxifene Hydrochloride/Raloxifene HCl CAS 82640-04-8;
Anti-Cancer API 99% Raloxifene HCl CAS 84449-90-1 For Cancer Treatment

Anti-Cancer API 99% Raloxifene hcl CAS 84449-90-1

Raloxifene Hydrochloride Use in Cancer
Raloxifene hydrochloride is approved to prevent: Breast cancer.
Raloxifene hydrochloride is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis.
Raloxifene hydrochloride is also approved to prevent and treat:Osteoporosis in postmenopausal women.
Raloxifene hydrochloride is also being studied in the treatment of other types of cancer.
 

Product nameRaloxifene hydrochloride
Other nameRaloxifene HCL;KEOXIFENE;AKOS 92138
Possible similar drugEvista; Evista
CAS register number82640-04-8
Steroid ClassAnti Estrogen Steroids
AppearanceLight yellow powder
Molecular formulaC28H28ClNO4S
Molecular weight510.04
Melting point250-253°C
Assay99%
Brandvanz
Manufacturervanz
Treatment  forthe treatment/prevention of osteoporosis and reduction of breast cancer riskinpostmenopausalwomen.
StorageShading, confined preservation


 
Certificate of Analysis

ITEMSSPECIFICATIONRESULT
AppearanceWhite &off-white powderConforms
GradeAnti Estrogen SteroidsConforms
SolubilitySoluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in waterConforms
IdentificationsInfrared AbsorptionConforms
Loss on drying≤0.5%0.4%
Residue on ignition≤0.1%0.06%
Heavy metals≤10ppmConforms
Raloxifene Impurity1≤0.20 %0.10%
Any unspecified individual impurity 2≤0.10%Max. 0.08%
Total impurities≤0.50%0.40%
Raloxifene HCl≥98.0%99.0%


We are also provide  :

pregabalin148553-50-8
Glutathione   70-18-8 
Ibudilast50847-11-5
Orlistat96829-58-2
Rapamycin53123-88-9
Sofosbuvir1190307-88-0
Galantamine Hydrobromide1953-4-4
DextroMethorphan HCL125-71-3
Memantine HCl41100-52-1
5a Hydrolaxogenin1177-71-5
Raloxifene hydrochloride82640-04-8
TUDCA14605-22-2
ITPP802590-64-3
Dutasteride164656-23-9
Finasteride98319-26-7
RU 58841154992-24-2
Triiodothyronine sodium55-06-1
L-Thyroxine51-48-9
Minoxidil38304-91-5
Enzalutamide 915087-33-1
Telmisartan144701-48-4
Yohimbine hydrochloride65-19-0
Oseltamivir phosphate204255-11-8
Everolimus  159351-69-6

 


Vinpocetine42971-09-5
Vincamine1617-90-9
phenibut1078-21-3
cdp-colina987-78-0
Citicoline sodium33818-15-4
IDRA-2122503-72-6
adrafinil63547-13-7
Melanotan2
Tianeptine Sulfate1224690-84-9
Tianeptine sodium30123-17-2
Tianeptine acid66981-73-5
magnesium L-Theorate778571-57-6
Sulbutiamine3286-46-2
NSI-189 Freebase and phosphate1270138-40-3
phenylpiracetam77472-70-9
Noopept157115-85-0
Alpha-GPC28319-77-9
Coluracetam  135463-81-9
Oxiracetam 62613-82-5
Piracetam  7491-74-9
NSI-1891270138-40-3
Sunifiram314728-85-3
Fasoracetam 110958-19-5
Citicoline sodium33818-15-4
Pramiracetam

Description:

Raloxifene hydrochlorideis an estrogen agonist/antagonist, commonly referred  to as a selective estrogen receptor modulator  (SERM) that belongs to the benzothiophene class of compounds.  Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4SHCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale yellow solid that  is very slightly  soluble in water.

EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 g of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrouslactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol,and titanium dioxide.

 

Application:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated. 

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). 

Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.



Raloxifene Hcl Application:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

Uses for Raloxifene Hydrochloride

Osteoporosis

Prevention of osteoporosis in postmenopausal women.

Treatment of osteoporosis in postmenopausal women.

Use supplemental calcium and/or vitamin D concomitantly if daily dietary intake is considered in adequate.


Corticosteroid-induced Osteoporosis

May prevent or treat corticosteroid-induced bone loss†. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

Breast Cancer

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. Not indicated for reduction in the risk of noninvasive breast cancer.


Ms. Gina
skype Ms. Gina
Manager
Tel: 86-27-88211875
Mobile: 188 7222 0799
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

Wuhan Yuancheng Gongchuang Technology Co,ltd [China (Mainland)]


Business Type:Manufacturer, Trading Company
City: Wuhan
Province/State: Hubei
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin Follow us on Twitter

Gina:   skype
Service:   skype

You May Like: